The product is being launched immediately, it added. Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma (cancer of plasma cells) and is also used to treat adult patients with mantle cell lymphoma (cancer of lymph nodes), the company said. The approved product has a market size of USD 1.172 billion for the 12 months ended March 2022, the company said citing IQVIA data.
The US Food and Drug Administration has given Aurobindo Pharma’s wholly-owned subsidiary Eugia Pharma Specialties Ltd final licence to manufacture and market its generic version of Bortezomib for injection, which is used to treat some forms of cancer. Aurobindo Pharma said in a regulatory filing that the US Food and Drug Administration (USFDA) has approved a single-dose vial of Bortezomib for injection with a strength of 3.5 mg per vial. The product is a generic version of Takeda Pharmaceuticals USA Inc.’s reference listed medication Velcade.
Suggestion For You:
For Latest News Follow us on Google News
- Show all
- Trending News
- Popular By week